Immunosuppressive therapy for steroid-resistant nephrotic syndrome: a Bayesian network meta-analysis of randomized controlled studies
- 184 Downloads
The purpose of this study was to conduct a meta-analysis examining the efficacy of cyclophosphamide, cyclosporin, and tacrolimus in treating steroid resistant nephrotic syndrome.
Medline, Cochrane, EMBASE, and Google Scholar were searched until May 02, 2017 using the keywords: immunosuppressive therapy, steroid-resistant nephrotic syndrome, cyclophosphamide, cyclosporine A, and tacrolimus. Inclusion criteria were randomized controlled trials (RCTs) including patients with SRNS treated with an immunosuppressive therapy or placebo.
Seven RCTs were included, and the number of patients ranged from 30 to 131. Conventional pair-wise meta-analysis indicated a higher odds of complete or partial remission with tacrolimus as compared to cyclophosphamide [odds ratio (OR) 4.908, 95% confidence interval (CI) 2.278–10.576, P < 0.001], and cyclophosphamide (OR 0.143, 95% CI 0.028–0.721, P = 0.019) and placebo (OR 0.043, 95% CI 0.012–0.157, P < 0.001) were associated with a lower likelihood of complete or partial remission than cyclosporine. Bayesian analysis indicated that tacrolimus and cyclosporine were the best and the second-best agents for inducing a complete or partial remission (rank probability = 0.53 for tacrolimus and 0.46 for cyclosporine).
As compared to cyclophosphamide and cyclosporin, tacrolimus is more effective at inducing remission in patients with SRNS.
KeywordsBayesian Cyclophosphamide Cyclosporin Meta-analysis Steroid-resistant nephrotic syndrome Tacrolimus
Compliance with ethical standards
This article does not contain any studies with human participants or animals performed by any of the authors.
Conflict of interest
The authors have declared that no conflict of interest exists.
Zhejiang Provincial Natural Science Fund LY17H050008, Zhejiang Provincial Medical Science and Technology Plan Projects 2017KY227.
- 6.Chapter 4: Steroid-resistant nephrotic syndrome in children. Kidney Int Suppl (2011). 2012; 2:172–6.Google Scholar
- 8.Plank C, Kalb V, Hinkes B, Hildebrandt F, Gefeller O, Rascher W. Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome—a randomized controlled multicentre trial by the Arbeitsgemeinschaft für Pädiatrische Nephrologie. Pediatr Nephrol. 2008;23(9):1483–93.CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Gulati A, Sinha A, Gupta A, Kanitkar M, Sreenivas V, Sharma J, Mantan M, Agarwal I, Dinda AK, Hari P, Bagga A. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney Int. 2012;82:1130–5.CrossRefPubMedGoogle Scholar
- 16.Hodson EM, Willis NS, Craig JC. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev. 2010;(11):CD003594. doi: 10.1002/14651858.CD003594.pub4
- 19.Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65–94.CrossRefPubMedGoogle Scholar
- 20.Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration; 2011. http://www.cochrane-handbook.org. Updated Mar 2011.
- 21.Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat. 1998;7:434–55.Google Scholar
- 31.Echeverri CV, Valencia GA, Higuita LM, Gayubo AK, Ochoa CL, Rosas LF, Muñoz LC, Sierra J, Zuleta JJ, Ruiz JJ. Immunosupressive therapy in children with steroid-resistant nephrotic syndrome: single center experience. J Bras Nefrol. 2013;35(3):200–5 [Article in English, Portuguese].CrossRefPubMedGoogle Scholar